<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04153110</url>
  </required_header>
  <id_info>
    <org_study_id>NP3244</org_study_id>
    <nct_id>NCT04153110</nct_id>
  </id_info>
  <brief_title>Cerebello-Spinal tDCS as Rehabilitative Intervention in Neurodegenerative Ataxia</brief_title>
  <acronym>SCA02</acronym>
  <official_title>Cerebello-Spinal tDCS as Rehabilitative Intervention in Neurodegenerative Ataxias: a Randomized, Double-blind, Sham-controlled Trial Followed by an Open-label Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neurodegenerative cerebellar ataxias represent a group of disabling disorders which currently
      lack effective therapies. Cerebellar transcranial direct current stimulation (tDCS) is a
      non-invasive technique, which has been demonstrated to modulate cerebellar excitability and
      improve symptoms in patients with cerebellar ataxias. In this randomized, double-blind,
      sham-controlled study followed by an open-label phase, the investigators will evaluate
      whether a repetition of two-weeks' treatment with cerebellar anodal tDCS and spinal cathodal
      tDCS, after a three months interval, may further outlast clinical improvement in patients
      with neurodegenerative cerebellar ataxia and can modulate cerebello-motor connectivity, at
      short and long term.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neurodegenerative cerebellar ataxias represent a heterogeneous group of disabling disorders
      in which progressive ataxia of gait, limb dysmetria, oculomotor deficits, dysarthria and
      kinetic tremor are the prominent clinical manifestations. Both the hereditary and sporadic
      forms usually present in young adulthood, and are characterized by atrophy of cerebellar or
      brainstem structures. Currently, cerebellar ataxia lack effective disease-modifying
      therapies.

      Cerebellar transcranial direct current stimulation (tDCS) is a non-invasive technique, which
      has been demonstrated to modulate cerebellar excitability and improve symptoms in patients
      with cerebellar ataxias. The present randomized, double-blind, sham-controlled study followed
      by an open-label phase will investigate a repetition of two-weeks' treatment with cerebellar
      anodal tDCS and spinal cathodal tDCS, after a three months interval, may further outlast
      clinical improvement in patients with neurodegenerative cerebellar ataxia and can modulate
      cerebello-motor connectivity, at short and long term. In addition the investigators will
      evaluate if tDCS intervention might improve cerebellar cognitive-affective syndrome in
      patients with ataxia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the International Cooperative Ataxia Rating Scale (ICARS) Score From Baseline</measure>
    <time_frame>Baseline - 2 weeks</time_frame>
    <description>International Cooperative Ataxia Rating Scale (ICARS): semi-quantitative 100-point scale, yielding a total score of 0 (no ataxia) to 100 (most severe ataxia).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the Scale for the Assessment and Rating of Ataxia (SARA) Score From Baseline</measure>
    <time_frame>Baseline - 2 weeks</time_frame>
    <description>Scale for the Assessment and Rating of Ataxia (SARA): 8-item performance based scale, yielding a total score of 0 (no ataxia) to 40 (most severe ataxia).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the Cerebellar cognitive affective syndrome (CCAS) Scale From Baseline</measure>
    <time_frame>Baseline - 2 weeks</time_frame>
    <description>CCAS/Schmahmann syndrome scale: 120 point scale, yielding a total score of 0 (most severe cognitive impairment) to 120 (no cognitive impairment).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the International Cooperative Ataxia Rating Scale (ICARS) Score From Baseline</measure>
    <time_frame>Baseline - 2 weeks - 3 month - 6 months - 9 months</time_frame>
    <description>International Cooperative Ataxia Rating Scale (ICARS): semi-quantitative 100-point scale, yielding a total score of 0 (no ataxia) to 100 (most severe ataxia).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Scale for the Assessment and Rating of Ataxia (SARA) Score From Baseline</measure>
    <time_frame>Baseline - 2 weeks - 3 month - 6 months - 9 months</time_frame>
    <description>Scale for the Assessment and Rating of Ataxia (SARA): 8-item performance based scale, yielding a total score of 0 (no ataxia) to 40 (most severe ataxia).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Cerebellar cognitive affective syndrome (CCAS) Scale From Baseline</measure>
    <time_frame>Baseline - 2 weeks - 3 month - 6 months - 9 months</time_frame>
    <description>CCAS/Schmahmann syndrome scale: 120 point scale, yielding a total score of 0 (most severe cognitive impairment) to 120 (no cognitive impairment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cerebellar Brain Inhibition (CBI) Measurements From Baseline</measure>
    <time_frame>Baseline - 2 weeks - 3 month - 6 months - 9 months</time_frame>
    <description>Cerebellar brain inhibition (CBI) is expressed as motor evoked potential amplitude (average of 10 recordings). Lower values reflect higher inhibition and thus reduced impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Short-Form Health Survey 36 (SF36) Score From Baseline</measure>
    <time_frame>Baseline - 2 weeks - 3 month - 6 months - 9 months</time_frame>
    <description>The Italian version of the Short-Form Health Survey 36 (SF-36): consists of 36 scaled score, yielding a total score of 0 (more disability) to 100 (less disability).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Ataxia</condition>
  <condition>Spinocerebellar Ataxias</condition>
  <condition>Spinocerebellar Ataxia Type 1</condition>
  <condition>Spinocerebellar Ataxia Type 2</condition>
  <condition>Spinocerebellar Ataxia 3</condition>
  <condition>Multiple System Atrophy</condition>
  <condition>Ataxia With Oculomotor Apraxia</condition>
  <condition>CANVAS</condition>
  <arm_group>
    <arm_group_label>Real tDCS - Real tDCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks) followed by an open-label 10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham tDCS - Real tDCS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>10 sessions of sham cerebellar and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks) followed by an open-label 10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Anodal cerebellar and cathodal spinal tDCS</intervention_name>
    <description>10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)</description>
    <arm_group_label>Real tDCS - Real tDCS</arm_group_label>
    <arm_group_label>Sham tDCS - Real tDCS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham cerebellar and sham spinal tDCS</intervention_name>
    <description>10 sessions of sham cerebellar and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)</description>
    <arm_group_label>Sham tDCS - Real tDCS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a cerebellar syndrome and quantifiable cerebellar atrophy

        Exclusion Criteria:

          -  Severe head trauma in the past

          -  History of seizures

          -  History of ischemic stroke or hemorrhage

          -  Pacemaker

          -  Metal implants in the head/neck region

          -  Severe comorbidity

          -  Intake of illegal drugs

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Borroni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Spedali Civili, Brescia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alberto Benussi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Università degli Studi di Brescia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Borroni, MD</last_name>
    <phone>+39 030 3995631</phone>
    <email>barbara.borroni@unibs.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alberto Benussi, MD</last_name>
    <phone>+39 030 3995631</phone>
    <email>benussialberto@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AO Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Borroni, MD</last_name>
      <phone>+39 030 3995631</phone>
      <email>bborroni@inwind.it</email>
    </contact>
    <contact_backup>
      <last_name>Alberto Benussi, MD</last_name>
      <phone>+39 030 3995631</phone>
      <email>benussialberto@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Barbara Borroni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alberto Benussi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Benussi A, Dell'Era V, Cantoni V, Bonetta E, Grasso R, Manenti R, Cotelli M, Padovani A, Borroni B. Cerebello-spinal tDCS in ataxia: A randomized, double-blind, sham-controlled, crossover trial. Neurology. 2018 Sep 18;91(12):e1090-e1101. doi: 10.1212/WNL.0000000000006210. Epub 2018 Aug 22.</citation>
    <PMID>30135258</PMID>
  </reference>
  <reference>
    <citation>Benussi A, Dell'Era V, Cotelli MS, Turla M, Casali C, Padovani A, Borroni B. Long term clinical and neurophysiological effects of cerebellar transcranial direct current stimulation in patients with neurodegenerative ataxia. Brain Stimul. 2017 Mar - Apr;10(2):242-250. doi: 10.1016/j.brs.2016.11.001. Epub 2016 Nov 3.</citation>
    <PMID>27838276</PMID>
  </reference>
  <reference>
    <citation>Benussi A, Koch G, Cotelli M, Padovani A, Borroni B. Cerebellar transcranial direct current stimulation in patients with ataxia: A double-blind, randomized, sham-controlled study. Mov Disord. 2015 Oct;30(12):1701-5. doi: 10.1002/mds.26356. Epub 2015 Aug 14.</citation>
    <PMID>26274840</PMID>
  </reference>
  <reference>
    <citation>Bikson M, Grossman P, Thomas C, Zannou AL, Jiang J, Adnan T, Mourdoukoutas AP, Kronberg G, Truong D, Boggio P, Brunoni AR, Charvet L, Fregni F, Fritsch B, Gillick B, Hamilton RH, Hampstead BM, Jankord R, Kirton A, Knotkova H, Liebetanz D, Liu A, Loo C, Nitsche MA, Reis J, Richardson JD, Rotenberg A, Turkeltaub PE, Woods AJ. Safety of Transcranial Direct Current Stimulation: Evidence Based Update 2016. Brain Stimul. 2016 Sep-Oct;9(5):641-661. doi: 10.1016/j.brs.2016.06.004. Epub 2016 Jun 15. Review.</citation>
    <PMID>27372845</PMID>
  </reference>
  <reference>
    <citation>Rossini PM, Burke D, Chen R, Cohen LG, Daskalakis Z, Di Iorio R, Di Lazzaro V, Ferreri F, Fitzgerald PB, George MS, Hallett M, Lefaucheur JP, Langguth B, Matsumoto H, Miniussi C, Nitsche MA, Pascual-Leone A, Paulus W, Rossi S, Rothwell JC, Siebner HR, Ugawa Y, Walsh V, Ziemann U. Non-invasive electrical and magnetic stimulation of the brain, spinal cord, roots and peripheral nerves: Basic principles and procedures for routine clinical and research application. An updated report from an I.F.C.N. Committee. Clin Neurophysiol. 2015 Jun;126(6):1071-1107. doi: 10.1016/j.clinph.2015.02.001. Epub 2015 Feb 10. Review.</citation>
    <PMID>25797650</PMID>
  </reference>
  <reference>
    <citation>Miranda PC, Salvador R, Wenger C, Fernandes SR. Computational models of non-invasive brain and spinal cord stimulation. Conf Proc IEEE Eng Med Biol Soc. 2016 Aug;2016:6457-6460. doi: 10.1109/EMBC.2016.7592207.</citation>
    <PMID>28269725</PMID>
  </reference>
  <reference>
    <citation>Lefaucheur JP, Antal A, Ayache SS, Benninger DH, Brunelin J, Cogiamanian F, Cotelli M, De Ridder D, Ferrucci R, Langguth B, Marangolo P, Mylius V, Nitsche MA, Padberg F, Palm U, Poulet E, Priori A, Rossi S, Schecklmann M, Vanneste S, Ziemann U, Garcia-Larrea L, Paulus W. Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS). Clin Neurophysiol. 2017 Jan;128(1):56-92. doi: 10.1016/j.clinph.2016.10.087. Epub 2016 Oct 29. Review.</citation>
    <PMID>27866120</PMID>
  </reference>
  <reference>
    <citation>Fiocchi S, Ravazzani P, Priori A, Parazzini M. Cerebellar and Spinal Direct Current Stimulation in Children: Computational Modeling of the Induced Electric Field. Front Hum Neurosci. 2016 Oct 17;10:522. eCollection 2016.</citation>
    <PMID>27799905</PMID>
  </reference>
  <reference>
    <citation>van Dun K, Bodranghien F, Manto M, Mariën P. Targeting the Cerebellum by Noninvasive Neurostimulation: a Review. Cerebellum. 2017 Jun;16(3):695-741. doi: 10.1007/s12311-016-0840-7. Review.</citation>
    <PMID>28032321</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <last_update_submitted>March 1, 2020</last_update_submitted>
  <last_update_submitted_qc>March 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia</investigator_affiliation>
    <investigator_full_name>Barbara Borroni</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Transcranial direct current stimulation</keyword>
  <keyword>Transcranial magnetic stimulation</keyword>
  <keyword>Spinocerebellar ataxia</keyword>
  <keyword>Cerebellar ataxia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Spinocerebellar Ataxias</mesh_term>
    <mesh_term>Spinocerebellar Degenerations</mesh_term>
    <mesh_term>Multiple System Atrophy</mesh_term>
    <mesh_term>Shy-Drager Syndrome</mesh_term>
    <mesh_term>Apraxias</mesh_term>
    <mesh_term>Machado-Joseph Disease</mesh_term>
    <mesh_term>Cogan Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT04153110/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

